SEOUL, Nov. 5 (Korea Bizwire) — Pharmaceutical companies are facing controversy as they were found to be avoiding manufacturing certain medicines for which authorities issued sales permits upon condition that they would be used for clinical trials on patients, if market reaction was ‘not good enough’. Rep. Jang Jeong-sook of the ruling Democratic Party, a [...]
Paris, France and Cambridge, Massachusetts, Oct. 16 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank [...]
PARIS, France and CAMBRIDGE, Massachusetts, Sept. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that detailed results of its phase II/III clinical trial of NBTXR3 in patients with soft tissue sarcoma (STS) will be presented by Dr. Sylvie Bonvalot, [...]
SYDNEY, Australia, Sept. 25 (Korea Bizwire) — SpeeDx Pty. Ltd. today announced the start of patient testing in their multisite U.S.-based clinical trials for ResistancePlus® MG (not available for sale in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen or MG, along with genetic markers [...]
EDMONTON, Alberta, Jul. 9 (Korea Bizwire) — Translational Research In Oncology (TRIO) today announced a collaboration with Novartis on its upcoming phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial will be called NATALEE (New Adjuvant TriAl with LEE). “Ribociclib in combination [...]
SEOUL, Jun. 23 (Korea Bizwire) — Novel Alzheimer’s disease (AD) medication developed by Megabiowood research team is planning for phase I clinical trial in next year. The novel medication is appraised to have high commercial possibilities as its aspects which shows non-cytotoxicity and superior absorbency that solves not only the symptoms but also the cause [...]
CAMBRIDGE, United Kingdom, Apr. 16 (Korea Bizwire) — AstraZeneca and MedImmune, its global biologics research and development arm, today presented efficacy and safety data from two Phase I trials evaluating Imfinzi (durvalumab) in combination with tremelimumab in 2nd-line immunotherapy-naïve patients with either non-squamous advanced non-small cell lung cancer (NSCLC) (Study 006) or metastatic urothelial carcinoma [...]
SYDNEY, Australia and MINNEAPOLIS, Dec. 14 (Korea Bizwire) — Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions, is pleased to announce the first prospective clinical trial [...]
SYDNEY, Australia, Dec. 4 (Korea Bizwire) — SpeeDx Pty. Ltd, a developer of advanced multiplex molecular diagnostic solutions, announced the incorporation of a US-based subsidiary company, SpeeDx Inc. The parent company, headquartered in Australia, will use the US base to support current clinical trial activity for ResistancePlus™ MG (not currently for sale in the US), [...]
GERMANTOWN, Md., Feb. 16 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder (MDD). NSI-189 is a new [...]